Related references
Note: Only part of the references are listed.How I treat cold agglutinin disease
Sigbjorn Berentsen
BLOOD (2021)
IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features
Surbhi Sidana et al.
LEUKEMIA (2020)
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstrom macroglobulinemia: the ASPEN study
Constantine S. Tam et al.
BLOOD (2020)
Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenstrom macroglobulinemia: long-term follow-up
Jorge J. Castillo et al.
BLOOD ADVANCES (2020)
Kidney diseases associated with Waldenstrom macroglobulinemia
Nupur N. Uppal et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2019)
Ibrutinib for the treatment of Bing-Neel syndrome, a complication of Waldenstrom macroglobulinemia: Patient case report
Lauren Hartsell et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2019)
CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenstrom macroglobulinaemia treated with ibrutinib
Jorge J. Castillo et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
IBRUTINIB MONOTHERAPY PRODUCES LONG-TERM DISEASE CONTROL IN PREVIOUSLY TREATED WALDENSTROM'S MACROGLOBULINEMIA. FINAL REPORT OF THE PIVOTAL TRIAL (NCT01614821).
S.P. Treon et al.
HEMATOLOGICAL ONCOLOGY (2019)
Progression Risk Stratification of Asymptomatic Waldenstrom Macroglobulinemia
Mark Bustoros et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase
Yunhang Guo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Treatment of Bing-Neel syndrome with first line sequential chemoimmunotherapy A case report
Maria Gavriatopoulou et al.
MEDICINE (2019)
Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study
Jorge J. Castillo et al.
BLOOD (2019)
Waldenstrom-associated anti-MAG paraprotein polyneuropathy with neurogenic tremor
Carlo Canepa
BMJ CASE REPORTS (2019)
Endobronchial involvement as an extremely rare manifestation of the Waldenstrom's disease
Hana Bartakova et al.
CLINICAL RESPIRATORY JOURNAL (2018)
Ibrutinib discontinuation in Waldenstrom macroglobulinemia: Etiologies, outcomes, and IgM rebound
Joshua N. Gustine et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenstrom macroglobulinemia
Jonas Paludo et al.
ANNALS OF HEMATOLOGY (2018)
Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study
Giuseppe Rossi et al.
BLOOD (2018)
Treatment of IgM-associated immunoglobulin light-chain amyloidosis with rituximab-bendamustine
Richa Manwani et al.
BLOOD (2018)
Immunoglobulin therapy in hematologic neoplasms and after hematopoietic cell transplantation
Masumi Ueda et al.
BLOOD REVIEWS (2018)
Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in Waldenstrom Macroglobulinemia
Jorge J. Castillo et al.
CLINICAL CANCER RESEARCH (2018)
Ibrutinib withdrawal symptoms in patients with Waldenstrom macroglobulinemia
Jorge J. Castillo et al.
HAEMATOLOGICA (2018)
Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies
Tina Bagratuni et al.
LEUKEMIA (2018)
Phase 3 Trial of Ibrutinib plus Rituximab in Waldenstrom's Macroglobulinemia
M. A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
The use of emergency apheresis in the management of plasma cell disorders
Sevgi Kalayoglu-Besisik
TRANSFUSION AND APHERESIS SCIENCE (2018)
Ibrutinib withdrawal symptoms in patients with Waldenstrom macroglobulinemia
Jorge J. Castillo et al.
HAEMATOLOGICA (2018)
Treatment and outcome patterns in European patients with Waldenstrom's macroglobulinaemia: a large, observational, retrospective chart review
Christian Buske et al.
LANCET HAEMATOLOGY (2018)
Predictors of symptomatic hyperviscosity in Waldenstrom macroglobulinemia
Jithma P. Abeykoon et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Ibrutinib Monotherapy in Symptomatic, Treatment-Naive Patients With Waldenstrom Macroglobulinemia
Steven P. Treon et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Autologous Stem Cell Transplant for IgM-Associated Amyloid Light-Chain Amyloidosis
M. Hasib Sidiqi et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Ibrutinib-Associated Atrial Fibrillation
Sarju Ganatra et al.
JACC-CLINICAL ELECTROPHYSIOLOGY (2018)
First report of ibrutinib in IgM-related amyloidosis: few responses, poor tolerability, and short survival
Tomas Pika et al.
BLOOD (2018)
BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years
Maria Gavriatopoulou et al.
BLOOD (2017)
Ibrutinib penetrates the blood brain barrier and shows efficacy in the therapy of Bing Neel syndrome
Christopher Mason et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome
Monique C. Minnema et al.
HAEMATOLOGICA (2017)
Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome
Monique C. Minnema et al.
HAEMATOLOGICA (2017)
Pattern of somatic mutations in patients with Waldenstrom macroglobulinemia or IgM monoclonal gammopathy of undetermined significance
Marzia Varettoni et al.
HAEMATOLOGICA (2017)
Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile
Tjeerd Barf et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2017)
Ibrutinib for patients with rituximab-refractory Waldenstrm's macro globulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial
Meletios A. Dimopoulos et al.
LANCET ONCOLOGY (2017)
Pattern of somatic mutations in patients with Waldenstrom macroglobulinemia or IgM monoclonal gammopathy of undetermined significance
Marzia Varettoni et al.
HAEMATOLOGICA (2017)
Once-weekly ofatumumab in untreated or relapsed Waldenstrom's macroglobulinaemia: an open-label, single-arm, phase 2 study
Richard R. Furman et al.
LANCET HAEMATOLOGY (2017)
Bing-Neel Syndrome: Illustrative Cases and Comprehensive Review of the Literature
Marzia Varettoni et al.
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES (2017)
TP53 Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia
Stephanie Poulain et al.
CLINICAL CANCER RESEARCH (2017)
Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenstrom macroglobulinaemia
Joshua N. Gustine et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
First report of MYD88L265P somatic mutation in IgM-associated light chain amyloidosis
Rajshekar Chakraborty et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2017)
Investigation and management of IgM and Waldenstrom-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panel
Shirley D'Sa et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Effective treatment of Bing-Neel Syndrome with oral fludarabine: a case series of four consecutive patients
Josephine M. I. Vos et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Central nervous system involvement by Waldenstrom macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study
Jorge J. Castillo et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Rituximab intolerance in patients with Waldenstrom macroglobulinaemia
Jorge J. Castillo et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Efficacy and long-term toxicity of the rituximab-fludarabine-cyclophosphamide combination therapy in Waldenstrom's macroglobulinemia
Laetitia Souchet et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Atrial fibrillation associated with ibrutinib in Waldenstrom macroglobulinemia
Joshua N. Gustine et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Treatment recommendations from the Eighth International Workshop on Waldenstrom's Macroglobulinemia
Veronique Leblond et al.
BLOOD (2016)
Renal disease related to Waldenstrom macroglobulinaemia: incidence, pathology and clinical outcomes
Josephine M. Vos et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
2016 US Lymphoid Malignancy Statistics by World Health Organization Subtypes
Lauren R. Teras et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2016)
Response rate to the treatment of Waldenstrom macroglobulinemia: A meta-analysis of the results of clinical trials
A. Santos-Lozano et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin M-Related Light Chain Amyloidosis
Sajitha Sachchithanantham et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Evolution of Management and Outcomes in Waldenstrom Macroglobulinemia: A Population-Based Analysis
Adam J. Olszewski et al.
ONCOLOGIST (2016)
Comparative Effectiveness of Rituximab-Based Immunochemotherapy in Waldenstrom's Macroglobulinemia (WM)
Adam J. Olszewski et al.
BLOOD (2016)
Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenstrom macroglobulinemia: final analysis of a phase 2 study
Efstathios Kastritis et al.
BLOOD (2015)
Competing risk survival analysis in patients with symptomatic Waldenstrom macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy
Efstathios Kastritis et al.
HAEMATOLOGICA (2015)
MYD88 Mutations and Response to Ibrutinib in Waldenstrom's Macroglobulinemia
Steven P. Treon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Ibrutinib in Previously Treated Waldenstrom's Macroglobulinemia
Steven P. Treon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Competing risk survival analysis in patients with symptomatic Waldenstrom macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy
Efstathios Kastritis et al.
HAEMATOLOGICA (2015)
Clinico-biological characteristics and treatment of type I monoclonal cryoglobulinaemia: a study of 64 cases
Stephanie Harel et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Pentostatin, cyclophosphamide and rituximab is a safe and effective treatment in patients with Waldenstrom's macroglobulinemia
Isabelle Herth et al.
LEUKEMIA & LYMPHOMA (2015)
Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenstrom's macroglobulinemia
Steven P. Treon et al.
BLOOD (2014)
Acute neurological worsening after Rituximab treatment in patients with anti-MAG neuropathy
Emilie Sala et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2014)
PARADOXICAL WORSENING OF ANTI-MYELIN-ASSOCIATED GLYCOPROTEIN POLYNEUROPATHY FOLLOWING RITUXIMAB
Michael D. Weiss et al.
MUSCLE & NERVE (2014)
Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN)
Meletios A. Dimopoulos et al.
BLOOD (2013)
Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenstrom's macroglobulinemia
Florence Nguyen-Khac et al.
HAEMATOLOGICA (2013)
Immunotherapy-based regimen in anti-MAG neuropathy: results in 45 patients
Marie-Anne Hospital et al.
HAEMATOLOGICA (2013)
Successful treatment of CANOMAD with IVIg and rituximab
Wolfgang N. Loescher et al.
JOURNAL OF NEUROLOGY (2013)
Rapid worsening of IgM anti-MAG demyelinating polyneuropathy during rituximab treatment
Abraham C. J. Stork et al.
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM (2013)
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
Mathias J. Rummel et al.
LANCET (2013)
Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy
Jean-Marc Leger et al.
NEUROLOGY (2013)
Progression in smoldering Waldenstrom macroglobulinemia: long-term results
Robert A. Kyle et al.
BLOOD (2012)
Clinical and prognostic implications of low or high level of von Willebrand factor in patients with Waldenstrom macroglobulinemia
Benedicte Hivert et al.
BLOOD (2012)
Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia An Effective but Myelosuppressive Regimen to Be Offered to Patients With Advanced Disease
Alessandra Tedeschi et al.
CANCER (2012)
Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2013 Featured Updates to the NCCN Guidelines
Kenneth C. Anderson et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2012)
The cryoglobulinaemias
Manuel Ramos-Casals et al.
LANCET (2012)
MYD88 L265P Somatic Mutation in Waldenstrom's Macroglobulinemia
Steven P. Treon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Neurophysiological and clinical responses to rituximab in patients with anti-MAG polyneuropathy
Gabriella Zara et al.
CLINICAL NEUROPHYSIOLOGY (2011)
B-cell-activating factor in rituximab-treated patients with anti-MAG polyneuropathy
Luana Benedetti et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2011)
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
Philippe Moreau et al.
LANCET ONCOLOGY (2011)
IgA and IgG hypogammaglobulinemia in Waldenstrom's macroglobulinemia
Zachary R. Hunter et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
High-Dose Therapy and Autologous Stem-Cell Transplantation in Waldenstrom Macroglobulinemia: The Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
Charalampia Kyriakou et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Placebo-Controlled Trial of Rituximab in IgM Anti-Myelin-Associated Glycoprotein Antibody Demyelinating Neuropathy
Marincis C. Dalakas et al.
ANNALS OF NEUROLOGY (2009)
Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003
Madhav V. Dhodapkar et al.
BLOOD (2009)
International prognostic scoring system for Waldenstrom macroglobulinemia
Pierre Morel et al.
BLOOD (2009)
Primary Therapy of Waldenstrom Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180
Steven P. Treon et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Targeting NF-κB in Waldenstrom macroglobulinemia
Xavier Leleu et al.
BLOOD (2008)
Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients:: a population-based study in Sweden
Sigurdur Y. Kristinsson et al.
BLOOD (2008)
Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: Results of WMCTG trial 03-248
Steven P. Treon et al.
CLINICAL CANCER RESEARCH (2007)
Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma
Wee J. Chng et al.
BLOOD (2006)
High-dose rituximab and anti-MAG-associated polyneuropathy
S Renaud et al.
NEUROLOGY (2006)
Characterization of familial Waldenstrom's macroglobulinemia
SP Treon et al.
ANNALS OF ONCOLOGY (2006)
Peripheral neuropathies in Waldenstrom's macroglobulinaemia
T Levine et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2006)
Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma
Constantine S. Tam et al.
CANCER (2006)
Waldenstrom's macroglobulinemia
MA Dimopoulos et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2005)
Worsening after rituximab treatment in anti-MAG neuropathy
L Broglio et al.
MUSCLE & NERVE (2005)
Multicenter phase 2 trial of rituximab for Waldenstrom macroglobulinemia (WM): An eastern cooperative oncology group study (E3A98)
MA Gertz et al.
LEUKEMIA & LYMPHOMA (2004)
Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies
S Renaud et al.
MUSCLE & NERVE (2003)
Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus panel recommendations from the second international workshop on Waldenstrom's macroglobulinemia
RG Owen et al.
SEMINARS IN ONCOLOGY (2003)
Prognostic factors in symptomatic Waldenstrom's macroglobulinemia
G Merlini et al.
SEMINARS IN ONCOLOGY (2003)
Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia:: Consensus panel recommendations from the second international workshop on Waldenstrom's macroglobulinemia
RA Kyle et al.
SEMINARS IN ONCOLOGY (2003)
Waldenstrom's macroglobulinemia: clinical course and prognostic factors in 60 patients - Experience from a single hematology unit
MC Kyrtsonis et al.
ANNALS OF HEMATOLOGY (2001)
The clinical spectrum of anti-GAD antibody-positive patients with stiff-person syndrome
MC Dalakas et al.
NEUROLOGY (2000)
Share Paper
